KRAS and cancer: Thus, SHP2 inhibition, which links RTKs to the RAS–RAF–MEK–ERK and RAS–PI3K–AKT–mTOR pathways, will be ineffective in KRAS-mutant or BRAF-mutant cancer cell lines.